TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Official title

Phase II Study of TMLI Administered in Combination With a Myeloablative Regimen (Cyclophosphamide + Etoposide) for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Overview

Single-arm, single-center phase II trial to evaluate the antileukemic activity and safety/tolerability of TMLI/cyclophosphamide and etoposide conditioning regimen followed by allogeneic hematopoietic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute myeloid leukemia.

Detailed description

The aim of this study is the evaluation of the antitumor activity of the conditioning regimen with TMLI, cyclophosphamide and etoposide followed by allogeneic hematopoietic stem cell transplantation by means of the progression-free survival at 2 years after a safety-lead phase.

The determination of the complete remission rate at day 30 post-transplant, the estimation of overall survival, the cumulative incidence of recurrence/progression, and non-relapse mortality at 100 days, 1 year, and 2 years, the Minima Residual Disease monitoring at 30, 90, 180, 270 days and 1 year, 1 year and a half and 2 years post-transplant, and the assessment early and late toxicities/complications by organ and severity, as well as dose/dose-volume toxicity characterization across organs, including acute/chronic graft-versus-host disease, infection, and long-term complications are included as secondary objectives.

Interventions

• Drug Total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide
  Evaluate the antileukemic activity of an total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide conditioning regimen for allogeneic hematopoietic stem cell transplantation

Primary outcome measures

• Progression-free survival [Time frame: From the start of therapy to 2 years after post-transplant]

Secondary outcome measures (9)

• Overall survival [Time frame: From the start of therapy to 2 years after post-transplant]
• Cumulative incidence of recurrence/progression [Time frame: From the start of therapy to 2 years after post-transplant]
• Complete remission rate [Time frame: From the day of infusion to the day 30 post-transplant]
• Non-relapse mortality [Time frame: From the start of therapy until 2 years after post-transplant]
• Measurable residual disease [Time frame: At 30, 90, 180 days and 1 year, 1.5 year and 2 years post-transplant]
• Incidence of infection [Time frame: 2 years after post-transplant]
• Adverse Events [Time frame: 2 years after post-transplant]
• Acute graft-versus-host disease grades 2-4 and 3-4 [Time frame: 100 days post-transplant]
• Chronic graft-versus-host disease [Time frame: 2 years after post-transplant]

Eligibility criteria

Inclusion criteria

• The participant has the ability and willingness to sign the informed consent document
• Age ≥18 to ≤50 years.
• Karnofsky's performance status should be ≥70%.
• Patients with myelodysplastic syndrome/acute myeloid leukemia or acute myeloid leukemia with relapsed/refractory active disease, or in complete remission or morphologic leukemia-free state with evidence of measurable residual disease as assessed by multiparameter flow cytometry (≥ 0,1%) or next-generation sequencing
• All candidates for this study must have an Human leukocyte antigens (A, B, C, DR) identical siblings who are willing to donate bone marrow or peripheral blood hematopoietic progenitors or an 8/8 matched unrelated donor. A single allele mismatch in A, B, C or DR beta chain 1 shall be allowed
• Total bilirubin ≤ 1.5 x upper limit of normal or 3 x upper limit of normal for Gilbert's disease.
• serum glutamate oxaloacetate transaminase \& serum glutamate pyruvate transaminaseT ≤ 5 x upper limit of normal.
• Serum creatinine ≤ 1.3 mg/dL or creatinine clearance measured ≥ 80 mL/min for 24 hours of urine collection
• Women of childbearing age only: Negative urine or serum pregnancy test
• Pulmonary function tests: forced expiratory volume in one second and Carbon Monoxide Diffusion Capacity (adjusted for Hb) ≥ 50% from expected normal value
• Patients should undergo cardiac evaluation with an electrocardiogram showing no ischemic changes or clinically relevant arrhythmia, and a ≥50% ejection fraction established by Multi-Gated Acquisition Scan or echocardiogram
• Men and women of childbearing potential agree to use appropriate contraceptives (hormonal or barrier contraception or abstinence) prior to study entry and for six months following the duration of study participation
• The time elapsed since the end of the last induction or reinduction cycle must be greater than or equal to 14 days

Exclusion criteria

• Patients who have received a previous autologous (within the last year) or allogeneic transplant (at any time) are excluded
• Previous radiation therapy, which would preclude the use of total bone marrow and lymphoid irradiation
• Plans during the trial to receive any other investigational (non-trial-related) agents
• Uncontrolled disease, including ongoing or active infection
• History of allergic reactions attributed to compounds of chemical or biological composition similar to cyclophosphamide or etoposide
• Patients with other active malignancies are not eligible for this study, other than the malignancies discussed
• Patients with a psychological or medical condition that the patient's physician deems unacceptable to proceed with allogeneic hematopoietic stem cell transplantation
• Women who plan to become pregnant or breastfeed during the trial
• Patients who do not agree to practice effective forms of contraception
• Subjects who, in the opinion of the investigator, may not be able to meet the safety control requirements of the study

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Other

Study locations

Spain · 1 center

• Hospital Universitario Virgen del Rocío — Seville

Identifiers

NCT: NCT06598969 · TMLI-MA

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗